Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Pre-Tax Margin
Income before tax as a percentage of revenue.
Utah Medical Products, Inc.NASDAQ: UTMD
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin narrows to 36.5%
Pre-tax margin was 36.5% in Q1 FY2026, down 3.2 pp from a year earlier. On a trailing-twelve-month basis it was 35.8%, down 4.6 pp year over year. Over 3 fiscal years it narrowed by 2.9 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 36.6%
- Year-over-year change
- -4.4pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.6% | -4.4pp |
| FY2024 | 2024-12-31 | 41.1% | +1.1pp |
| FY2023 | 2023-12-31 | 40.0% | +0.5pp |
| FY2022 | 2022-12-31 | 39.5% | +0.7pp |
| FY2021 | 2021-12-31 | 38.9% | — |
Pre-Tax Margin vs competitors
How UTMD compares with its peers on the latest reported figures
- UTMD's LTM Mar 2026 pre-tax margin of 35.8% is the highest of the 11 companies compared; the peer median is -64.7%.
- Its year-over-year change of -4.6 pp is the 8th highest of 11, against a peer median of +13.2 pp.
- Over three fiscal years its change of -2.9 pp compares with a peer median of +25.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 35.8% | -4.6 pp | -2.9 pp | |
| LTM Mar 2026 | 25.2% | +16.6 pp | +19.6 pp | |
| LTM Mar 2026 | 8.3% | +3.5 pp | +7.3 pp | |
| LTM Mar 2026 | -5.2% | +9.9 pp | +31.9 pp | |
| LTM Mar 2026 | -24.6% | +29.8 pp | +30.9 pp | |
| LTM Mar 2026 | -64.5% | +78.3 pp | +1676.2 pp | |
| LTM Mar 2026 | -64.8% | -45.9 pp | -54.1 pp | |
| LTM Mar 2026 | -206.5% | +64.8 pp | +161.9 pp | |
| LTM Mar 2026 | -368.3% | -306.6 pp | -296.0 pp | |
| LTM Mar 2026 | -519.6% | +1013.3 pp | +85.6 pp | |
| LTM Mar 2026 | -18194.2% | -12290.7 pp | -11606.6 pp | |
| Peer median (excluding UTMD) | -64.7% | +13.2 pp | +25.3 pp | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.05M | 52.28M | 50.22M | 40.9M | 38.52M |
| Cost of Revenue | 18.14M | 20.09M | 20.19M | 16.76M | 18.65M |
| Gross Profit | 30.92M | 32.2M | 30.04M | 24.14M | 19.88M |
| Gross Margin | 63.0% | 61.6% | 59.8% | 59.0% | 51.6% |
| Research & Development | 526K | 493K | 560K | 813K | 668K |
| Selling, General & Admin | 11.51M | 11.91M | 12.7M | 5.57M | 7.81M |
| Operating Expenses | 12.04M | 12.41M | 13.26M | 10.55M | 8.47M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.77M | 2.95M |
| EBITDA | 26.35M | 27.74M | 24.75M | 19.57M | 17.06M |
| EBITDA Margin | 53.7% | 53.1% | 49.3% | 47.9% | 44.3% |
| Operating Income | 18.88M | 19.79M | 16.78M | 13.59M | 11.4M |
| Operating Margin | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Interest Income | 166K | 661K | 0 | 3.37M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 181K | 869K | 3.31M | 3.21M | 2.71M |
| Income Before Tax | 19.06M | 20.66M | 20.09M | 16.8M | 14.11M |
| Pre-Tax Margin | 38.9% | 39.5% | 40.0% | 41.1% | 36.6% |
| Income Tax Expense | 4.27M | 4.19M | 3.45M | 2.93M | 2.82M |
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Net Margin | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| EPS (Basic) | 4.05 | 4.53 | 4.57 | 3.96 | 3.41 |
| EPS (Diluted) | 4.04 | 4.52 | 4.57 | 3.96 | 3.48 |
| Weighted Avg Shares | 3.65M | 3.64M | 3.64M | 3.5M | 3.31M |
| Weighted Avg Shares (Diluted) | 3.66M | 3.64M | 3.64M | 3.5M | 3.24M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.